MedTrace Logo

The Efficacy of Phosphatidylserine-Omega3 in Elderly With Age Associated Memory Impairment

NCT00437983 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 157

Last updated 2010-01-05

Study results available
· View outcomes & findings →

Summary

The primary objective of this trial is to assess the ability of an oral administration of Phosphatidylserine-Omega3 to improve attention and memory complaints in comparison to placebo in age associated memory impaired subjects.

Conditions

  • Age Associated Memory Impairment

Interventions

DIETARY_SUPPLEMENT

PS-Omega3

Phosphatidylserine-Omega3 capsules 3x100mg/day 15 wk. Next, follow up phase, open label,1x100mg/day, 15 wk

DIETARY_SUPPLEMENT

Placebo

Placebo cellulose tainted with fishy odor capsules 3x100mg/day 15 wk

Sponsors & Collaborators

  • Enzymotec

    lead INDUSTRY

Principal Investigators

  • Amos Korczyn, MD · Sourasky Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2008-06-30
Completion
2008-09-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00437983 on ClinicalTrials.gov